Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Clinical trial NCT05539430 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05539430
- Sponsor
- Legend Biotech USA Inc
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-18
- Primary completion
- 2027-12-01
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.